Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1121-1140 of 3,900 trials

Persistent Corneal Epithelial Defects: NEXAGON Gel Study

We are evaluating the safety and effectiveness of NEXAGON (Lufepirsen Ophthalmic Gel) for individuals with persistent corneal epithelial defects. The study aims to see if it helps heal the cornea better than a placebo.

Persistent Corneal Epithelial DefectEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesOphthalmology

Viral Lung Infection: Tozorakimab Study

We are testing the new medication tozorakimab in patients hospitalized for viral lung infections requiring oxygen. The goal is to see if it can help prevent serious complications compared to a placebo.

Acute Respiratory FailureSevere Viral Lung Infections≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Plaque Psoriasis: JNJ-77242113 Treatment Study

We are studying a new medication for people with moderate to severe plaque psoriasis. The goal is to see if it works better than a placebo in reducing symptoms.

Plaque Psoriasis>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteDermatology

Long-Term Study on Gene-Modified Cell Treatments

We are evaluating the long-term health effects of gene-modified cells in participants, especially children and adolescents. This includes monitoring for serious side effects and overall growth and development.

Solid and Hematological Malignancies>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncologyRheumatology

Generalized Myasthenia Gravis: Iptacopan Study

We are studying a new treatment called iptacopan for people with generalized Myasthenia Gravis to see if it helps improve daily activities and muscle strength. The trial will also assess the safety of this treatment compared to a placebo.

AChR Myasthenia Gravis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementInternal MedicineNeurology

Autoimmune Cytopenias: Povetacicept Study

We are testing a new treatment called povetacicept for individuals with autoimmune cytopenias. The study aims to evaluate its safety and effectiveness in managing this condition.

Autoimmune Cytopenias6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Multiple Myeloma: Testing ISB 2001

We are investigating a new drug called ISB 2001 for patients with relapsed or refractory multiple myeloma. This trial aims to see how well it works in treating this challenging condition.

Relapsed/Refractory Multiple Myeloma1-2 yearsSafety phase (I)HematologyOncology

Cirrhosis Treatment: Albumin and Enoxaparin Study

We are testing a new combination therapy of albumin and enoxaparin for patients with decompensated cirrhosis at high risk of complications. The study aims to assess safety and explore how this treatment may affect the disease.

Cirrhosis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Leucettinib-21: Safety and Effects Study

We are investigating the safety and effects of Leucettinib-21 in healthy individuals and patients with Down Syndrome and Alzheimer’s. This study aims to understand how the drug works in different populations.

Healthy ParticipantsSafety phase (I)Neurology

Vitamin D Supplementation in Obese Children and Adolescents

We are comparing monthly versus daily vitamin D supplements to see which is more effective in raising vitamin D levels in obese children and teens. The study also looks at safety and how well participants follow the treatment.

Obesity in Children and Adolescents>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesEndocrinologyPediatrics

Pain Management in Laparoscopic Colorectal Surgery: Comparing Two Techniques

We are studying the effectiveness of two pain relief methods after laparoscopic colorectal surgery. Our goal is to find out which method reduces opioid use and improves recovery.

Patients Scheduled for Laparoscopic Colorectal Surgery1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

Advanced Solid Tumors: INCB161734 Treatment

We are testing a new drug for patients with advanced or metastatic solid tumors that have the KRAS G12D mutation. The study aims to understand the safety and dosage of this treatment.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Prostate Cancer: uPAR PET Imaging Study

We are investigating a new imaging method to help classify prostate cancer grades in men with localized, untreated disease. This study aims to assess the safety and effectiveness of this non-invasive technique.

Prostate Cancer≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Chronic Immune Thrombocytopenia: Kedrion IVIg Treatment

We are studying a new intravenous treatment for adults with chronic immune thrombocytopenia to see if it can increase platelet counts and reduce bleeding. This trial will help us understand how well this treatment works and its safety.

Chronic Immune Thrombocytopenia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Melanoma Treatment: Daromun Injection Study

We are studying whether intratumoral injections of Daromun can help patients with Stage IIIB/C melanoma live longer and reduce the chance of cancer returning after surgery. This trial compares the new treatment to standard surgery and therapy.

Stage III Superficial Spreading Melanoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Breast Cancer: Vepdegestrant and Samuraciclib Study

We are investigating the safety and effectiveness of a new oral medication combined with another treatment for adults with advanced or metastatic hormone receptor-positive breast cancer. This study aims to find better treatment options for patients facing this condition.

Advanced Breast CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Scleroderma-Related Lung Disease: Investigational Treatments

We are studying new treatments for interstitial lung disease in people with scleroderma to see if they improve lung function and overall health compared to a placebo.

Interstitial Lung Disease due to Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonologyRheumatology

Labor Induction: Outpatient vs. Inpatient Methods

We are studying whether inducing labor at home is as safe and effective as doing it in a hospital. We want to understand the costs and experiences of women and healthcare staff in both settings.

Induction of Labour3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Non-Small Cell Lung Cancer: Divarasib with Other Therapies

We are studying the safety and effectiveness of divarasib combined with pembrolizumab and chemotherapy in patients with untreated advanced lung cancer that has a KRAS G12C mutation. This research aims to find the best dose and treatment approach.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Zilovertamab Vedotin for Pediatric Cancers

We are studying a new treatment for children and young adults with blood cancers and solid tumors. The trial aims to assess its safety and how well it may work in these young patients.

Blood Cancers and Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPediatrics